Quoin Pharmaceuticals Releases Fourth Episode of NETHERTON NOW Video Series Featuring Mandy Aldwin-Easton, a Prominent Patient Advocate

Quoin Pharmaceuticals releases the fourth episode of the "NETHERTON NOW" video series, featuring patient advocate Mandy Aldwin-Easton. The series highlights the challenges of living with Netherton Syndrome and the need for effective treatments. Quoin's lead product candidate, QRX003, is advancing in pivotal clinical trials, with recent data showing promising improvements in key clinical outcomes.

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has released the fourth episode of its "NETHERTON NOW" video series, featuring Mandy Aldwin-Easton, a patient advocate and Medical and Communications Manager for the UK-based Ichthyosis Support Group and President of the European Network for Ichthyosis. The episode highlights the challenges of living with Netherton Syndrome and underscores the urgent need for effective treatments. The video series aims to raise awareness and provide hope to those living with this rare and often misunderstood condition.

Netherton Syndrome is a severe, life-threatening condition characterized by excruciating pain, debilitating flare-ups, recurrent infections, and emotional trauma. Despite having a supportive family and medical advocacy, Mandy Aldwin-Easton has experienced extreme flare-ups, prolonged hospitalizations, and a lack of targeted treatment options throughout her life. Her story serves as a powerful reminder of the physical and emotional toll of the disease.

Quoin Pharmaceuticals is committed to addressing the unmet medical needs of patients with rare and orphan diseases. The company's lead product candidate, QRX003, is a topical lotion formulated with a proprietary delivery technology designed to treat Netherton Syndrome. Recent clinical data from ongoing trials have shown highly encouraging improvements in key clinical outcomes, suggesting that QRX003 may provide a meaningful treatment for this severely underserved community.

In addition to the release of the new video episode, Quoin Pharmaceuticals reported positive clinical data for its ongoing pediatric Netherton Syndrome study in the second quarter of 2025. The company also announced that the FDA has cleared a second pivotal study of QRX003 for Netherton Syndrome, and that it has received Orphan Drug Designation from the European Medicines Agency and Rare Pediatric Disease Designation from the U.S. FDA for QRX003. These regulatory milestones are expected to accelerate the development and approval of QRX003.

Quoin Pharmaceuticals is dedicated to driving forward research that addresses the significant unmet needs across a broader range of rare skin disorders. The company's innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications.

References:
[1] https://finance.yahoo.com/news/quoin-pharmaceuticals-releases-fourth-episode-123000605.html
[2] https://www.biospace.com/press-releases/quoin-pharmaceuticals-announces-second-quarter-2025-financial-results-and-corporate-update